TIDMPRTC
PureTech Health PLC
08 July 2020
8 July 2020
PureTech Health plc
PureTech Founded Entity Sonde Health Launches New Voice-Enabled
Health Screening Tool to Potentially Help Employers Return to Work
During the Global Pandemic
Sonde One combines 6-second voice analysis, CDC-informed
COVID-19 questionnaire and body temperature reading in one app
PureTech Health plc (LSE: PRTC) ("PureTech" or the "Company"), a
clinical-stage biotherapeutics company dedicated to discovering,
developing and commercialising highly differentiated medicines for
devastating diseases, is pleased to note that its Founded Entity,
Sonde Health, has launched Sonde One, a new voice-enabled health
detection and monitoring app to potentially help employers improve
employee safety, meet government mandates and satisfy their own
administrative needs as they reopen office doors in a rapidly
changing COVID-19 environment.
The announcement from Sonde Health is below:
Sonde Health Launches New Voice-Enabled Health Screening Tool to
Help Employers Return to Work During the Global Pandemic
Sonde One combines 6-second voice analysis, COVID-19
questionnaire, and body temperature reading in one app
BOSTON-July 8, 2020- As businesses across the country grapple
with how to safely bring employees back to the physical workplace,
a new voice-enabled health detection and monitoring app from Sonde
Health promises to potentially help employers improve employee
safety, meet government mandates, and satisfy their own
administrative needs as they reopen office doors in a rapidly
changing COVID-19 environment.
The new tool, called Sonde One , leverages the company's
advanced vocal biomarker platform and machine learning technology.
With a single 6-second voice sample, the app is designed to quickly
and objectively detect respiratory symptoms, such as coughing,
shortness of breath, or chest tightness or pain. The app combines
this voice analysis with a comprehensive, CDC-informed COVID-19
questionnaire and user inputted body temperature to give employees
clear instructions about where they can work within one minute.
Employers can deploy the solution to any number of staff anywhere
and make daily informed decisions regarding who can go into the
workplace or who should work from home, without requiring new
equipment or workflows.
"At Sonde, we believe that voice is a vital sign and a
meaningful predictor of health," said David Liu, Chief Executive
Officer for Sonde Health. "By analysing a few seconds of speech, we
can detect subtle changes in a person's voice caused by common
symptoms of respiratory disease. We built this capability into the
Sonde One app so organisations can provide their employees with
simple and fast COVID-19 monitoring in their pocket."
To bring Sonde One to market, Sonde has partnered with corporate
wellness solutions provider Wellworks for You to make the tool
available to its clients and their 1.4 million participating
members. SHI International, a 5,000-person global provider of
technology products and services, is the first enterprise to enrol.
The company will begin implementing the Sonde One app in August, as
it gradually begins bringing employees back to the workplace,
starting with its Somerset, NJ headquarters.
"After months of remote work and distributed workforces, many
employers want to get their employees back in the office; they're
just not sure of the best way to do it," says Thomas Tegler,
President of Wellworks for You. "At Wellworks for You, we're always
seeking better ways to promote employee wellness and preventative
care, and in today's healthcare climate, Sonde Health provides a
novel solution. Sonde One is an easy, non-invasive way for
organisations to manage employee health risks during the pandemic
and potentially get workers back to the office safely."
"As we navigate this pandemic, our employees' health and
wellness is our top priority," says Michael Haluska, Vice President
of Human Resources for SHI International. "From the conference room
to the warehouse floor, the Sonde One app will help us standardise
our return to work policy to eliminate any confusion and keep all
employees feeling safe."
Sonde One can be customised to each employer's return to work
policy, giving employees clear guidance on whether they should or
should not report for physical duty following each screening.
Additionally, a QR code can be delivered to employees within the
app and scanned at an organisation's front door to confirm
compliance with protocols. Secure and customisable reporting
capabilities enable employers to confirm employee participation,
satisfy enterprise needs, and adhere to mandatory state guidelines
surrounding employee screening and documentation.
Once an employer signs on, employees can download their
employer-specific app via the App Store or Google Play on any
smartphone, allowing for fast, simple deployment across
enterprises.
For more information about Sonde One, visit
https://www.sondehealth.com/app-page .
About Sonde Health
Leveraging 300,000 voice samples from over 50,000 individuals,
Sonde Health's voice-based technology platform is designed to
detect health conditions and symptoms from changes in voice. In
seconds, Sonde's proprietary technology senses and analyses subtle
changes in the voice due to changes in a person's physiology to
create a range of measurements that provide early health detection
and monitoring. www.sondehealth.com
About Wellworks For You
Wellworks For You is a Corporate Wellness and Mental Well-Being
Management Company, headquartered in Malvern, PA., focusing on high
touch customer service. We provide customised wellness solutions
for organisations throughout the world.
Press note - SHI CEO Thai Lee is an investor in Sonde
Health.
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercialising highly
differentiated medicines for devastating diseases, including
intractable cancers, lymphatic and gastrointestinal diseases,
central nervous system disorders and inflammatory and immunological
diseases, among others. The Company has created a broad and deep
pipeline through the expertise of its experienced research and
development team and its extensive network of scientists,
clinicians and industry leaders. This pipeline, which is being
advanced both internally and through PureTech's Founded Entities,
is comprised of 24 products and product candidates, including two
that have been cleared by the US Food and Drug Administration
(FDA). All of the underlying programmes and platforms that resulted
in this pipeline of product candidates were initially identified or
discovered and then advanced by the PureTech team through key
validation points based on the Company's unique insights into the
biology of the brain, immune and gut, or BIG, systems and the
interface between those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media US media
Allison Mead Talbot Ben Atwell, Rob Winder Stephanie Simon
+1 617 651 3156 +44 (0) 20 3727 1000 +1 617 581 9333
amt@puretechhealth.com ben.atwell@FTIconsulting.com stephanie@tenbridgecommunications.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAFXPEASEEEA
(END) Dow Jones Newswires
July 08, 2020 08:32 ET (12:32 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024